Skip to main content
. 2024 Nov 3;15:9495. doi: 10.1038/s41467-024-53821-1

Fig. 1. Molecular landscape of the GIST cohort.

Fig. 1

a Each column represents an individual tumor (n = 78). Patients with paired tumor and normal samples are separated into two groups: WGS (n = 19) and WES (n = 59). The top panel shows information about the clinical risk stratification, mutated exon of KIT or PDGFRA, primary tumor sites, and TKI treatment information. Each subsequent panel displays a specific molecular profile. NA, not available. Samples are ranked according to the risk stratification followed by the TMB. In the top panel, TKI indicates TKI treatment prior to surgery (tumor collection), and the GIST samples show pathologically progression (resistance) on TKIs before samples were collected. DEL, deletion; BND, translocation; INV, inversion; DUP, duplication. b Boxplots showing that the alternation burdens increase with risk stratification. Left, TMB of coding mutations, L (n = 23), I (n = 5), H (n = 22), and M (n = 23). Center, the percentage of CNV segments in autosomal genome region, L (n = 23), I (n = 5), H (n = 22), and M (n = 23). Right, the number of SVs in 19 WGS tumors, L (n = 8), H (n = 6), and M (n = 4). c Number of clone (left) and subclone (right) mutations in coding region among different risk stratification. L (n = 15), I (n = 5), H (n = 16), and M (n = 19). The P values in (b, c) are calculated using the two-sided wilcoxon rank-sum test (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). L denotes low-risk, I denotes intermediate-risk, H denotes high-risk, M denotes metastatic. The low, centerline, and upper of boxplot represent the first quartile, the median, and the third quartile of data, respectively. The whiskers extend to the largest and smallest values within 1.5 times the interquartile range (IQR). Source data are provided as a Source Data file.